Ozempic vs Victoza 2026: Weight Loss & Diabetes Comparison
Ozempic and Victoza are both GLP-1 receptor agonists, but Ozempic is dosed weekly while Victoza requires daily injections, and Ozempic has demonstrated superior weight loss (up to 22% body weight reduction) compared to Victoza (up to 6% body weight reduction) in clinical trials.
Ozempic (semaglutide)
Weekly injectable GLP-1 receptor agonist for type 2 diabetes with potent weight loss and cardiovascular benefits.
Patients seeking maximum weight loss, those with poor medication adherence, individuals eligible for obesity indication, and patients needing cardiovascular protection.
Victoza (liraglutide)
Daily injectable GLP-1 receptor agonist for type 2 diabetes with established long-term safety record.
Patients preferring daily dosing with flexible adjustments, those who need rapid dose escalation, and individuals primarily focused on glucose control rather than weight loss.
Quick Answer
AI SummaryOzempic and Victoza are both GLP-1 receptor agonists, but Ozempic is dosed weekly while Victoza requires daily injections, and Ozempic has demonstrated superior weight loss (up to 22% body weight reduction) compared to Victoza (up to 6% body weight reduction) in clinical trials.
Our Verdict
AI-assistedChoose Ozempic if you prioritize maximum weight loss, need less frequent dosing (weekly vs daily), or want a medication approved for both diabetes and obesity treatment. Choose Victoza if you prefer daily injections with faster dose adjustments, require tighter glycemic control with more frequent medication adjustments, or have cost concerns and lack comprehensive insurance coverage.
Was this verdict helpful?
Choose Ozempic (semaglutide) if
Best pickPatients seeking maximum weight loss, those with poor medication adherence, individuals eligible for obesity indication, and patients needing cardiovascular protection.
Choose Victoza (liraglutide) if
Patients preferring daily dosing with flexible adjustments, those who need rapid dose escalation, and individuals primarily focused on glucose control rather than weight loss.
Track this comparison
Get notified when prices change, new specs ship, or our verdict updates.
Triggers: price change new spec verdict update
No spam. Stop anytime.
Key Differences at a Glance
- Injection Frequency:✓ Ozempic (semaglutide) wins(Once weekly vs Once daily)
- Average Weight Loss at Maximum Dose:✓ Ozempic (semaglutide) wins(Up to 22% vs Up to 6%)
- FDA Approval for Weight Loss (Type 2 Diabetes):✓ Ozempic (semaglutide) wins(Yes (as Wegovy for obesity, Ozempic for diabetes) vs Type 2 diabetes only)
Key Facts & Figures
26 numeric metrics compared
| Metric | Ozempic (semaglutide) | Victoza (liraglutide) | Ratio |
|---|---|---|---|
| Dosing Frequency(times per week) | 1x weekly | — | — |
| Time to Maximum Dose(weeks) | 4 weeks | — | — |
| FDA Approval Year (for weight loss)(year) | 2021 (Wegovy) | — | — |
| Average Monthly Cost (Uninsured)(USD) | $1,100 | $750 | |
| Clinical Trial Duration(weeks) | 68 weeks (STEP) | — | — |
| FDA Approval Year | 2017 | — | — |
| Maximum Weekly Dose(mg) | 2.0 mg | — | — |
| HbA1c Reduction (Type 2 Diabetes)(%) | 1.5-1.8% | — | — |
| Average Weight Loss in Pivotal Trial(lbs) | 4-6 lbs (secondary outcome) | — | — |
| Nausea Incidence Rate(%) | 25-40% | — | — |
| Insurance Coverage Rate for Primary Indication(%) | 85% (diabetes) | — | — |
| CVOT Cardiovascular Risk Reduction(%) | 26% | — | — |
| Trial Duration for Primary Endpoint(weeks) | 52 weeks (SUSTAIN-6) | — | — |
| Maximum Weight Loss at Highest Approved Dose(%) | 22% | 6% | |
| A1C Reduction (Average)(mmol/mol) | 1.5-1.8% | 1.2-1.5% | |
| Half-Life Duration(hours) | 168 hours (7 days) | 13 hours | |
| Average Monthly Cost (Without Insurance)(USD) | $1,100 | $950 | |
| Time to Reach Steady State(weeks) | 4-5 weeks | 1-2 weeks | |
| GI Side Effect Incidence Rate(%) | 32% | 26% | |
| Years on Market(years) | 11 years (since 2013) | 15 years (since 2009) | |
| Injection Frequency | Once weekly | Once daily | |
| Average Body Weight Loss(%) | 15% | 5.6% | |
| Cardiovascular Event Reduction(%) | 26% (SUSTAIN-6) | 13% (LEADER) | |
| Maximum Approved Dose(mg) | 2.4 mg weekly | 1.8 mg daily | |
| Years Since FDA Approval(years) | 7 years (2017) | 16 years (2010) | |
| Nausea Incidence in Trials(%) | 25-39% | 20-30% |
Sourced from publicly available data ·
Key Differences
7 attributes compared head-to-head
- Once weekly(winner)Injection FrequencyOnce daily
- Up to 22%(winner)Average Weight Loss at Maximum DoseUp to 6%
- Yes (as Wegovy for obesity, Ozempic for diabetes)(winner)FDA Approval for Weight Loss (Type 2 Diabetes)Type 2 diabetes only
- 7 days(winner)Active Ingredient Half-Life13 hours
- $900-$1,300Typical Monthly Cost (Without Insurance)$800-$1,100(winner)
- 1.5-1.8%A1C Reduction (Diabetes Patients)1.5-1.8%
- 4-5 weeksTime to Reach Steady State1-2 weeks(winner)
- Injection Frequency
Ozempic (semaglutide)
Once weekly(winner)
Victoza (liraglutide)
Once daily
- Average Weight Loss at Maximum Dose
Ozempic (semaglutide)
Up to 22%(winner)
Victoza (liraglutide)
Up to 6%
- FDA Approval for Weight Loss (Type 2 Diabetes)
Ozempic (semaglutide)
Yes (as Wegovy for obesity, Ozempic for diabetes)(winner)
Victoza (liraglutide)
Type 2 diabetes only
- Active Ingredient Half-Life
Ozempic (semaglutide)
7 days(winner)
Victoza (liraglutide)
13 hours
- Typical Monthly Cost (Without Insurance)
Ozempic (semaglutide)
$900-$1,300
Victoza (liraglutide)
$800-$1,100(winner)
- A1C Reduction (Diabetes Patients)
Ozempic (semaglutide)
1.5-1.8%
Victoza (liraglutide)
1.5-1.8%
- Time to Reach Steady State
Ozempic (semaglutide)
4-5 weeks
Victoza (liraglutide)
1-2 weeks(winner)
Full Comparison
| Attribute | Ozempic (semaglutide) | Victoza (liraglutide) |
|---|---|---|
| Average Weight Loss(%) | 15% | — |
| Time to Maximum Dose(weeks) | 4 weeks | — |
| Maximum Weight Loss at Highest Approved Dose(%) | 22%(winner) | 6% |
| A1C Reduction (Average)(mmol/mol) | 1.5-1.8%(winner) | 1.2-1.5% |
| Average Body Weight Loss(%) | 15%(winner) | 5.6% |
| Dosing Frequency(times per week) | 1x weekly | — |
| FDA Approval Year (for weight loss)(year) | 2021 (Wegovy) | — |
| Average Monthly Cost (Uninsured)(USD) | $1,100 | $750(winner) |
| Average Monthly Cost (Without Insurance)(USD) | $1,100 | $950(winner) |
| Clinical Trial Duration(weeks) | 68 weeks (STEP) | — |
| FDA Approval Year | 2017 | — |
| Maximum Weekly Dose(mg) | 2.0 mg | — |
| Maximum Approved Dose(mg) | 2.4 mg weekly | 1.8 mg daily |
| HbA1c Reduction (Type 2 Diabetes)(%) | 1.5-1.8% | — |
| Average Weight Loss in Pivotal Trial(lbs) | 4-6 lbs (secondary outcome) | — |
| Nausea Incidence Rate(%) | 25-40% | — |
| GI Side Effect Incidence Rate(%) | 32% | 26%(winner) |
| Nausea Incidence in Trials(%) | 25-39% | 20-30%(winner) |
| Insurance Coverage Rate for Primary Indication(%) | 85% (diabetes) | — |
| CVOT Cardiovascular Risk Reduction(%) | 26% | — |
| Trial Duration for Primary Endpoint(weeks) | 52 weeks (SUSTAIN-6) | — |
| Half-Life Duration(hours) | 168 hours (7 days)(winner) | 13 hours |
| Time to Reach Steady State(weeks) | 4-5 weeks | 1-2 weeks(winner) |
| Years on Market(years) | 11 years (since 2013) | 15 years (since 2009)(winner) |
| Injection Frequency | Once weekly(winner) | Once daily |
| Cardiovascular Event Reduction(%) | 26% (SUSTAIN-6)(winner) | 13% (LEADER) |
| Years Since FDA Approval(years) | 7 years (2017)(winner) | 16 years (2010) |
Pros & Cons
10 pros·4 cons across both
Ozempic (semaglutide)
Pros
- Once-weekly injection significantly improves medication adherence
- Proven to reduce body weight by up to 22% in clinical trials
- Longer half-life (7 days) provides more stable glucose control
- FDA-approved for both type 2 diabetes and chronic weight management (as Wegovy)
- Cardiovascular benefits demonstrated in SUSTAIN-6 trial with 26% reduction in major adverse events
Cons
- Higher out-of-pocket costs for uninsured patients ($900-$1,300/month)
- Gastrointestinal side effects (nausea, vomiting) occur in 25-39% of users, especially at higher doses
Victoza (liraglutide)
Pros
- Daily dosing allows for more flexible titration and faster dose adjustments
- Reaches steady state in 1-2 weeks compared to 4-5 weeks for Ozempic
- Slightly lower cost at $800-$1,100 per month without insurance
- Well-established 10+ year safety track record with extensive real-world data
- Demonstrated 13% cardiovascular event reduction in LEADER trial
Cons
- Requires daily injections, reducing adherence compared to weekly alternatives
- Significantly lower weight loss (up to 6%) versus Ozempic's 22%
Frequently Asked Questions
5 questions
Ozempic is significantly more effective for weight loss, with clinical trials showing up to 22% body weight reduction compared to Victoza's up to 6%. The STEP trials (Ozempic/Wegovy) demonstrated an average 15.3% weight loss at the 2.4mg dose, while Victoza achieved approximately 5.9% in comparative studies. This 266% greater weight loss is Ozempic's most significant clinical advantage.
Resources & Learn More
Curated sources to dive deeper
Where to Buy
As an affiliate, we may earn a commission from qualifying purchases at no extra cost to you. Learn more about our affiliate disclosure
Wikipedia
- W
Ozempic (semaglutide) on Wikipedia (opens in new tab)
Weekly injectable GLP-1 receptor agonist for type 2 diabetes with potent weight loss and cardiovascular benefits.
- W
Victoza (liraglutide) on Wikipedia (opens in new tab)
Daily injectable GLP-1 receptor agonist for type 2 diabetes with established long-term safety record.
Related Comparisons
12 more to explore
Ozempic vs Victoza
healthOzempic vs Saxenda
healthOzempic vs Zepbound
healthYoga vs Pilates
healthIbuprofen vs Acetaminophen
healthInvisalign vs Traditional Braces
healthWhey Protein vs Casein Protein
healthCrossFit vs Gym Training
healthFlu Shot vs COVID Vaccine
healthOrganic Food vs Non-Organic Food
healthTherapy vs Medication
healthMeditation vs Yoga
health
Related Articles
1 article
Explore More
Related comparisons and categories